Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gastrointestinal 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 4Neoplasm Metastasis 2Mastocytosis, Systemic 2Sarcoma 1Recurrence 1Melanoma 1Lung Neoplasms 1Leukemia, Mast-Cell 1Core Binding Factor Acute Myeloid Leukemia 1Colorectal Neoplasms 1

Interventions

Doxorubicin 62Ifosfamide 39Gemcitabine 29Radiotherapy 27Filgrastim 27Cyclophosphamide 26Docetaxel 19Vincristine 18pembrolizumab 17Etoposide 17pazopanib 16Cisplatin 16Nivolumab 15Trabectedin 14apatinib 13Magnetic Resonance Spectroscopy 13Carboplatin 12Irinotecan 11Bevacizumab 11anlotinib 10Temozolomide 10Surgical Procedures, Operative 10Sirolimus 10camrelizumab 9Sorafenib 9Paclitaxel 9Ipilimumab 9Injections 9Dactinomycin 9Topotecan 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sarcoma × avapritinib × Clear all
NCT04771520 2026-03-02

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Recruiting
50 enrolled
DermatologicGastrointestinalSarcomaThoracic

Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡